Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses?

/ Publications / Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses?

Navigated laser in diabetic macular edema: the impact of reduced injection burden on patients and physicians-who wins and who loses?

Authors: Menzler J,Neubauer A,Ziemssen F.
Presented: January 1, 2019
Type: Publications

Summary: “Due to patients’ higher therapy adherence, physicians using navigated laser therapy with anti-VEGF generate similar or higher revenues compared to VEGF monotherapy in all analyzed countries. The use of Navilas decreases the patient’s injection burden at the same clinical outcome, while the physician’s revenue remained stable or increased. Therewith, therapy discontinuation in DME can be reduced using the combination therapy with Navilas.”

Related publications and webinars

From Minimally Invasive Procedure to Photocoagulation: Personalized retinal care with Navilas® (Japanese)

  • Type:
  • Presented:February 8, 2024
Priv.-Doz. Dr. med. Yoko Miura

On-Demand Webinar: Navilas in der täglichen Praxis

  • Type:
  • Presented:February 1, 2017
Dr. Bernd Fassebender
  • The treatment strategy and selected parameters presented in content listed here are solely the responsibility of the treating ophthalmologist, who is required to be familiar with the most recent literature/guidelines or recommendations, as well as with the usage of the Navilas Laser System according to the current Operator’s Manual.